Comments: Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

[no abstract]

Saved in:

Bibliographic Details
Main Authors:	Lim, Sun Min, Tan, Jiunn-Liang, Dias, Josiane Mourao, Voon, Pei Jye, How, Soon Hin, Zhou, Xiangdong, Xiong, Hailin, Massuti, Bartomeu, Medley, Louise C., Nagasaka, Misako, Vicente, David, Girard, Nicolas, Rittmeyer, Achim, Botesteanu, Dana-Adriana, Alhadab, Ali, Mahoney, Janine M., Zhang, Jie, Bauml, Joshua Michael, Baig, Mahadi, Scott, Susan Combs
Format:	Article
Published:	American Society of Clinical Oncology 2024
Subjects:	R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Online Access:	http://eprints.um.edu.my/46894/ https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8612
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!